Litcius/Paper detail

Everolimus, an mTORC1/2 inhibitor, in ART-suppressed individuals who received solid organ transplantation: A prospective study

Timothy J. Henrich, Corinna Schreiner, Cheryl Cameron, Louise E. Hogan, Brian Richardson, Rachel L. Rutishauser, Amelia N. Deitchman, Simon N. Chu, Rodney Rogers, Cassandra Thanh, Erica A. Gibson, Arya Zarinsefat, Sonia Bakkour, Francesca Aweeka, Michael P. Busch, Teri Liegler, Christopher C. Baker, Jeffrey M. Milush, Steven G. Deeks, Peter G. Stock

2020American Journal of Transplantation31 citationsDOIOpen Access PDF

Topics & Concepts

EverolimusMedicinePI3K/AKT/mTOR pathwayTransplantationmTORC1Clinical trialKidney transplantationOncologyInternal medicineProspective cohort studySirolimusPharmacologyBiologySignal transductionBiochemistryHIV/AIDS drug development and treatmentHIV Research and TreatmentRenal Transplantation Outcomes and Treatments
Everolimus, an mTORC1/2 inhibitor, in ART-suppressed individuals who received solid organ transplantation: A prospective study | Litcius